WHITE PLAINS, N.Y. and KANSAS CITY, Kan., Jan. 7 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) and The University of Kansas Cancer Center have announced a partnership to translate discoveries by LLS-funded researchers into Phase I clinical trials.
Currently, The University of Kansas Cancer Center (KU Cancer Center) and its partner, Beckloff Associates Inc., are supporting two early stage projects of LLS-funded researchers at The University of Virginia and The University of Toronto. The number of projects is expected to expand over the year.
The University of Kansas is uniquely positioned to work with LLS to accelerate the research it funds. KU Cancer Center has a long history of developing cancer drugs and currently has the No. 1 pharmacy school, in terms of National Institutes of Health (NIH) funding. KU Cancer Center holds a development contract with the National Cancer Institute (NCI) and has helped formulate seven out of the 19 drugs developed through NCI's Developmental Therapeutics Program.
Integral to moving projects rapidly into clinical trials is KU Cancer Center's partnership with industry. Beckloff Associates Inc., based in Overland Park, KS, provides development and regulatory support on the projects. Through these collaborative efforts and the formation of multi-disciplinary, multi-organizational, high-performance project teams, drug projects are advanced rapidly.
The partnership between KU Cancer Center and LLS is part of LLS's Therapy Acceleration Program, which supports private sector and academic-based projects with the goal of moving blood cancer therapies into the development pipeline. KU Cancer Center is the first academic partner in the program.
"By leveraging the capabilities and strengths The University of Kansas has in place, this partnership brings
'/>"/>
SOURCE The Leukemia & Lymphoma Society Copyright©2009 PR Newswire. All rights reserved | |
Page: 1 2 3 Related medicine news :1.
Grape Seed Extract Kills Leukemia Cells in Lab2.
Stem cells and leukemia battle for marrow microenvironment3.
Biopure Submits IND Application for Proposed Clinical Trial in Patients with Acute Myeloid Leukemia4.
Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting5.
Dismissed leukemia drug helps cll patients, studies show6.
Novel treatments show improvements in survival and response rates for leukemia and lymphoma7.
Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma8.
50 years of hairy-cell leukemia research to be observed9.
Higher Chemo Drug Dose Prolongs Lives of Leukemia Patients10.
Adult survivors of childhood leukemia have lower bone mineral density, study finds11.
UCSD researchers identify potential new drug target for chronic leukemia